CDC42 effector protein 4Genealiases: BORG4 · CEP4 · KAIA1777
Q-omics provides the consensus-scored CDC42EP4 profile across patient tissues and cancer cell-line models. CDC42EP4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CDC42EP4 is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, CDC42EP4 protein abundance shows 20,499 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight HNSC, KICH, and LUAD as cancer lineages where CDC42EP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDC42EP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDC42EP4 survival associations across molecular data types. CDC42EP4 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDC42EP4 RNA expression–survival associations across cancer types. High CDC42EP4 expression shows unfavorable associations in THYM and LIHC, but favorable associations in HNSC, KIRC, BRCA and CESC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CDC42EP4 RNA expression.
This table summarizes CDC42EP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in LIHC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for CDC42EP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDC42EP4 shows lower tumor expression in KICH, UCEC and READ and higher tumor expression in LIHC, HNSC and KIRP. The KICH box plot shows higher CDC42EP4 RNA expression in normal versus tumor tissue (log2 FC = −2.192, t-test p < 0.001).
This table shows molecular features associated with CDC42EP4 in patient tissues and cancer cell lines. In patient samples, CDC42EP4 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, CDC42EP4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
